JP2019530473A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019530473A5 JP2019530473A5 JP2019533714A JP2019533714A JP2019530473A5 JP 2019530473 A5 JP2019530473 A5 JP 2019530473A5 JP 2019533714 A JP2019533714 A JP 2019533714A JP 2019533714 A JP2019533714 A JP 2019533714A JP 2019530473 A5 JP2019530473 A5 JP 2019530473A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- polypeptide compound
- amino acid
- peptide
- acid residues
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 32
- 229920001184 polypeptide Polymers 0.000 claims 23
- 102000004196 processed proteins & peptides Human genes 0.000 claims 23
- 150000001875 compounds Chemical class 0.000 claims 22
- 235000001014 amino acid Nutrition 0.000 claims 13
- 150000001413 amino acids Chemical class 0.000 claims 13
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 12
- 125000000539 amino acid group Chemical group 0.000 claims 11
- 238000000034 method Methods 0.000 claims 9
- 102000004877 Insulin Human genes 0.000 claims 8
- 108090001061 Insulin Proteins 0.000 claims 8
- 229940125396 insulin Drugs 0.000 claims 6
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 3
- 230000001590 oxidative effect Effects 0.000 claims 3
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 108010075254 C-Peptide Proteins 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 101000976075 Homo sapiens Insulin Proteins 0.000 claims 2
- 108010043958 Peptoids Proteins 0.000 claims 2
- 230000002378 acidificating effect Effects 0.000 claims 2
- 235000018417 cysteine Nutrition 0.000 claims 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 2
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 claims 2
- 125000006239 protecting group Chemical group 0.000 claims 2
- 125000006850 spacer group Chemical group 0.000 claims 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 claims 1
- 102000004142 Trypsin Human genes 0.000 claims 1
- 108090000631 Trypsin Proteins 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 239000011630 iodine Substances 0.000 claims 1
- 238000010647 peptide synthesis reaction Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 239000007790 solid phase Substances 0.000 claims 1
- 239000012588 trypsin Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GR20160100458 | 2016-09-06 | ||
| GR20160100458 | 2016-09-06 | ||
| PCT/IB2017/055336 WO2018047062A1 (en) | 2016-09-06 | 2017-09-05 | Proinsulin derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019530473A JP2019530473A (ja) | 2019-10-24 |
| JP2019530473A5 true JP2019530473A5 (https=) | 2020-10-15 |
Family
ID=59895344
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019533714A Pending JP2019530473A (ja) | 2016-09-06 | 2017-09-05 | プロインスリン誘導体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11230585B2 (https=) |
| EP (1) | EP3509625A1 (https=) |
| JP (1) | JP2019530473A (https=) |
| KR (1) | KR20190043609A (https=) |
| CN (1) | CN110234339A (https=) |
| AU (1) | AU2017322552B2 (https=) |
| BR (1) | BR112019004314A2 (https=) |
| CA (1) | CA3035850A1 (https=) |
| IL (1) | IL265182A (https=) |
| WO (1) | WO2018047062A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3756679A1 (en) | 2019-06-28 | 2020-12-30 | Université de Genève | Compositions for use in the treatment of insulin deficiency conditions |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK58285D0 (da) | 1984-05-30 | 1985-02-08 | Novo Industri As | Peptider samt fremstilling og anvendelse deraf |
| DK129385A (da) | 1985-03-22 | 1986-09-23 | Novo Industri As | Peptider og fremstilling deraf |
| DK10191D0 (da) | 1991-01-22 | 1991-01-22 | Novo Nordisk As | Hidtil ukendte peptider |
| US5304473A (en) * | 1991-06-11 | 1994-04-19 | Eli Lilly And Company | A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production |
| WO1995016708A1 (en) | 1993-12-17 | 1995-06-22 | Novo Nordisk A/S | Proinsulin-like compounds |
| BR9408638A (pt) | 1994-12-29 | 2004-09-21 | Bio Technology General Corp | Geração de insulina humana |
| CN1231259C (zh) * | 1994-12-29 | 2005-12-14 | 萨文特医药公司 | 生产人胰岛素 |
| EP0741188A3 (en) | 1995-05-05 | 1999-07-14 | Eli Lilly And Company | Single chain insulin with high bioactivity |
| US6444641B1 (en) | 1997-10-24 | 2002-09-03 | Eli Lilly Company | Fatty acid-acylated insulin analogs |
| JP2001521006A (ja) | 1997-10-24 | 2001-11-06 | イーライ・リリー・アンド・カンパニー | 不溶性インシュリン組成物 |
| GB9812675D0 (en) | 1998-06-11 | 1998-08-12 | Univ Edinburgh | Peptides |
| EP1193272B1 (en) | 2000-10-02 | 2004-06-30 | Yonsei University | Single-chain insulin analogs |
| KR100449454B1 (ko) * | 2000-10-02 | 2004-09-21 | 이현철 | 단일사슬 인슐린 유도체의 유전자를 포함하는 당뇨병치료용 벡터 |
| WO2002079251A2 (en) * | 2001-04-02 | 2002-10-10 | Novo Nordisk A/S | Method for making human insulin precursors |
| EP1692168B1 (en) | 2003-12-03 | 2011-07-20 | Novo Nordisk A/S | Single-chain insulin |
| JP2008533100A (ja) | 2005-03-18 | 2008-08-21 | ノボ ノルディスク アクティーゼルスカブ | Ｐｅｇ化された単鎖インスリン |
| US20090069216A1 (en) | 2006-02-21 | 2009-03-12 | Novo Nordisk A/S | Single-Chain Insulin Analogues and Pharmaceutical Formulations Thereof |
| JP2009530243A (ja) | 2006-03-13 | 2009-08-27 | ノボ・ノルデイスク・エー／エス | アシル化単鎖インスリン |
| WO2008043033A2 (en) | 2006-10-04 | 2008-04-10 | Case Western Reserve University | Fibrillation-resistant insulin and insulin analogues |
| US10100098B2 (en) * | 2006-12-13 | 2018-10-16 | Stelis Biopharma Private Limited | Insulin production methods and proinsulin constructs |
| GR1006941B (el) * | 2009-06-01 | 2010-08-27 | Χημικα Και Βιοφαρμακευτικα Εργαστηρια Πατρων Αε (Cbl-Patras), | Πεπτιδικη συνθεση (peptide synthesis) |
| GR1007010B (el) | 2009-10-08 | 2010-10-07 | Χημικα Και Βιοφαρμακευτικα Εργαστηρια Πατρων Αε (Cbl-Patras), | Ινσουλινοειδη πεπτιδια |
| GB201321489D0 (en) * | 2013-12-05 | 2014-01-22 | Chemical & Biopharmaceutical Lab Of Patras S A | Biologically active insulin derivatives |
| US9982287B2 (en) * | 2013-12-17 | 2018-05-29 | Novo Nordisk A/S | Enterokinase cleavable polypeptides |
-
2017
- 2017-09-05 EP EP17768522.9A patent/EP3509625A1/en not_active Withdrawn
- 2017-09-05 WO PCT/IB2017/055336 patent/WO2018047062A1/en not_active Ceased
- 2017-09-05 CN CN201780067797.9A patent/CN110234339A/zh active Pending
- 2017-09-05 KR KR1020197009616A patent/KR20190043609A/ko not_active Ceased
- 2017-09-05 CA CA3035850A patent/CA3035850A1/en active Pending
- 2017-09-05 JP JP2019533714A patent/JP2019530473A/ja active Pending
- 2017-09-05 US US16/330,154 patent/US11230585B2/en active Active
- 2017-09-05 BR BR112019004314A patent/BR112019004314A2/pt not_active IP Right Cessation
- 2017-09-05 AU AU2017322552A patent/AU2017322552B2/en active Active
-
2019
- 2019-03-05 IL IL265182A patent/IL265182A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8999940B2 (en) | Analogues of glucose-dependent insulinotropic polypeptide (GIP) modified at N-terminal | |
| CN102171244B (zh) | 糖依赖性胰岛素释放肽的类似物 | |
| CN103596583B (zh) | 新型胰高血糖素类似物 | |
| CA2890719C (en) | Long-acting single-chain insulin analogues | |
| CN108271356A (zh) | 肠降血糖素-胰岛素缀合物 | |
| JP2016512255A5 (https=) | ||
| CN102105159A (zh) | 基于gip的混合激动剂用于治疗代谢紊乱和肥胖症 | |
| RU2015101697A (ru) | Аналоги глюкагона, обладающие активностью рецептора gip | |
| CN105324397A (zh) | 胰岛素-肠促胰岛素缀合物 | |
| JP2011524420A5 (https=) | ||
| CA2462462A1 (en) | Peptides acting as both glp-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use | |
| JP2012530145A5 (https=) | ||
| JP2007537141A (ja) | 新規なｇｌｐ−１化合物 | |
| RU2012105355A (ru) | Производное аналога glp-1 или его фармацевтически приемлемые соли и их применение | |
| AU2013337250A1 (en) | Long-acting single-chain insulin analogues | |
| EP3883957A1 (en) | Single-chain insulin analogues with poly-alanine c-domain sub-segments | |
| CA2988841C (en) | Protease-resistant lipidated glp-1 analogs | |
| KR20180014754A (ko) | 페길화된 옥신토모둘린 변이체 | |
| JP2019530473A5 (https=) | ||
| US9624287B2 (en) | O-linked carbohydrate-modified insulin analogues | |
| EP2877200B1 (en) | O-linked carbohydrate-modified insulin analogues | |
| CN115279341A (zh) | 胰高血糖素类似物的液体制剂 | |
| JP2019520336A5 (https=) | ||
| AU2013237740B2 (en) | Insulin analogues containing penta-fluora-phenyalanine at position B24 | |
| JP2019530473A (ja) | プロインスリン誘導体 |